N4,N4’-(ethane-1,2-diyl)bis(6-chloropyrimidine-4,5-diamine) | 23124-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N4,N4’-(ethane-1,2-diyl)bis(6-chloropyrimidine-4,5-diamine)
• 英文别名: 1,2-Bis-<4-chlor-5-amino-pyrimidinyl-(6)-amino>-aethan；6,6'-dichloro-N⁴,N⁴'-ethane-1,2-diyl-bis-pyrimidine-4,5-diamine；4-N-[2-[(5-amino-6-chloropyrimidin-4-yl)amino]ethyl]-6-chloropyrimidine-4,5-diamine
• CAS: 23124-14-3
• 化学式: C₁₀H₁₂Cl₂N₈
• 分子量: 315.165
• InChiKey: GAHYPBSBYUMRRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Compounds for treating cystic fibrosis
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

  公开号：US10414768B2

  公开（公告）日：2019-09-17

  The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).

  本发明涉及式（I）化合物或其药学上可接受的对映体、盐、溶液剂或原药。本发明还涉及式（I）化合物用于治疗囊性纤维化的用途。本发明还涉及一种制造式（I）化合物的工艺。
• COMPOUNDS FOR TREATING CYSTIC FIBROSIS
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

  公开号：US20170362239A1

  公开（公告）日：2017-12-21

  The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).
• [EN] COMPOUNDS FOR TREATING CYSTIC FIBROSIS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE LA FIBROSE KYSTIQUE
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2016087665A2

  公开（公告）日：2016-06-09

  The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).